Trial Profile
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Ductal carcinoma; HER2 positive breast cancer
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 03 Feb 2020 Planned primary completion date changed from 31 Mar 2019 to 30 Jun 2020.
- 14 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.